Literature DB >> 8861636

Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

J M Benítez del Castillo1, A Castillo, N Toledano, S Durán, C del Aguila, M Otero, J García-Sanchez.   

Abstract

The corneal stroma is the major barrier to penetration for the lipophilic Cyclosporine A (CsA) molecule and prevents the use of the common ophthalmic solvents. At present, corn oil, castor oil and olive oil are the three most commonly used vehicles. The aim of this study was to determine the effect that topically applied CsA dissolved in different oils has on corneal epithelial permeability measured by fluorophotometry. Forty healthy volunteers, with absence of ocular or systemic disease and not receiving topical or systemic drugs were enrolled. Measurements were taken before and 45 min after the instillation of 40 microliters of a 2% aqueous solution of sodium fluorescein without preservatives. Basal corneal permeability and the permeability 24 h after the instillation of 2% CsA-olive oil, olive oil alone, 2% CsA-castor oil, castor oil alone, 2% CsA-corn oil and corn oil alone, were calculated. To prepare the topical 2% CsA, a Sandimmun oral solution (Sandoz, Basel, Switzerland) was employed under sterile conditions. We found that epithelial permeability 24 h after the instillation of any CsA formulations or solvents increased more than 6.62 times (p <0.001). No differences in corneal permeability values were found between any of the CsA formulations and the vehicles. We conclude that oils used to dissolve CsA are mainly responsible for the increased corneal epithelial permeability. No differences were found in the effects of the tested solvents on corneal epithelial permeability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8861636     DOI: 10.1007/bf01204623

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  23 in total

1.  Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.

Authors:  A G Secchi; M S Tognon; A Leonardi
Journal:  Am J Ophthalmol       Date:  1990-12-15       Impact factor: 5.258

Review 2.  Update on topical cyclosporin A. Background, immunology, and pharmacology.

Authors:  M W Belin; C S Bouchard; T M Phillips
Journal:  Cornea       Date:  1990-07       Impact factor: 2.651

Review 3.  Histopathology of cyclosporine nephrotoxicity.

Authors:  M J Mihatsch; G Thiel; B Ryffel
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

4.  New trends in non-antigen-specific immunosuppression.

Authors:  J F Bach
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

5.  Statistical analysis of multi-eye data in ophthalmic research.

Authors:  W A Ray; D M O'Day
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-08       Impact factor: 4.799

6.  [Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results].

Authors:  L Goichot-Bonnat; P Chemla; Y Pouliquen
Journal:  J Fr Ophtalmol       Date:  1987       Impact factor: 0.818

7.  Influence of artificial tears on corneal epithelium in dry-eye syndrome.

Authors:  M Göbbels; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

8.  Topically applied cyclosporine in azone prolongs corneal allograft survival.

Authors:  C Newton; B M Gebhardt; H E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-02       Impact factor: 4.799

9.  Effects of artificial tears on corneal epithelial permeability in dry eyes.

Authors:  M Göbbels; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

10.  Topical cyclosporine in high-risk corneal transplants.

Authors:  M W Belin; C S Bouchard; S Frantz; J Chmielinska
Journal:  Ophthalmology       Date:  1989-08       Impact factor: 12.079

View more
  1 in total

1.  Prolonging survival of corneal transplantation by selective sphingosine-1-phosphate receptor 1 agonist.

Authors:  Min Gao; Yong Liu; Yang Xiao; Gencheng Han; Liang Jia; Liqiang Wang; Tian Lei; Yifei Huang
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.